Deimmunised Haemophilia A Therapeutic - Biotest AG
Alternative Names: Deimmunised FVIII-Tregitope; Haemophilia A Therapeutic Reduced Immunogenicity; HAT RILatest Information Update: 17 Mar 2025
At a glance
- Originator Biotest AG
- Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
- Mechanism of Action Factor VIII replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Haemophilia A
Highest Development Phases
- Preclinical Haemophilia
Most Recent Events
- 17 Mar 2025 Preclinical development in Haemophilia is ongoing in the USA and Germany (Parenteral) (Biotest AG pipeline, March 2025)
- 28 Aug 2024 No recent reports of development identified for preclinical development in Haemophilia in Germany (Parenteral)
- 28 Aug 2024 No recent reports of development identified for preclinical development in Haemophilia in USA (Parenteral)